A sponsor focused guide to clinical trials in Japan, covering PMDA regulation, Clinical Trial Notification timelines, leading research sites, patient access, therapeutic strengths, and Japan's strategic role in Asia Pacific drug development.
Japan is the world's third-largest economy (GDP ~$4.2 trillion) and home to 125 million people; the world's most rapidly aging major population, with one of the highest life expectancies on earth (83.5 years average). As home to globally significant pharmaceutical companies including Takeda, Astellas, Daiichi Sankyo, Eisai, and Ono Pharmaceutical, Japan is both a major drug discovery nation and an essential regulatory market for any global drug development program. Approval by the Pharmaceuticals and Medical Devices Agency (PMDA) is increasingly required for market access across much of Asia.
Clinical trials are regulated by the PMDA under the Ministry of Health, Labour and Welfare (MHLW). Japan's Clinical Trial Notification (CTN) system gives sponsors a 30-day review window; if no concerns are raised, the trial may commence automatically. Japan's 2023 median marketing authorization approval time of 332 days was on par with the US (333 days) and significantly faster than Europe (453 days). PMDA opened its first overseas offices in Bangkok (July 2024) and Washington D.C. (November 2024); signaling Japan's ambition to become a more internationally integrated regulatory center.
Japan's 125 million people are among the world's most homogeneous (approximately 98% ethnic Japanese); a characteristic that, while limiting diversity, makes Japan uniquely valuable for Japanese-specific pharmacogenomics data and for demonstrating safety in East Asian genetic backgrounds. The country's extreme aging is its defining epidemiological feature: Japan has the world's highest proportion of people over 65 (~29%), creating massive and growing demand for research in oncology, neurodegenerative diseases, cardiovascular conditions, and metabolic disorders.
Japan's universal health insurance system (NHI) covers the entire population through a network of approximately 8,000 hospitals and 100,000+ clinics. The country is particularly valuable for oncology trials addressing gastric cancer, liver cancer, lung cancer, and hematologic malignancies; all of which have distinct prevalence or genetic variant profiles in Japanese patients compared to Western populations.
The reimbursement advantage: Unlike the EU where drugs must go through a separate Health Technology Assessment (HTA) process after EMA approval (which can add years), Japan conducts pricing and reimbursement review in parallel with the PMDA marketing authorization. Once MHLW grants approval, the drug is typically listed with a price and covered by insurance within 60–90 days; making Japan one of the world's fastest countries from approval to patient access.
Japan's case for inclusion in global programs rests on four pillars: regulatory equivalence (PMDA approval is increasingly a gateway to Taiwan, South Korea, and other Asian markets via abridged review processes), FDA-equivalent data quality (zero OAI inspections over 15 years), a rapidly aging patient population ideal for age-related disease research, and a unique SMO infrastructure that actually accelerates trial startup versus other major markets.
30-day CTN review; 332-day median MAA approval (=US, faster than EU); PMDA now in Project Orbis for concurrent oncology review with FDA, EMA, TGA, Health Canada, MHRA, and ANVISA; English CTD modules accepted from Sept 2024.
PMDA approval acts as a gateway to Taiwan, Malaysia, Singapore, and the Philippines via abridged review processes. Parallel pricing and reimbursement means approval-to-market in 60–90 days; Japan approval equals instant pricing, unlike EU's post-approval HTA delay.
125M people; world's oldest major population (29% over 65); high chronic disease burden; unique East Asian pharmacogenomics data; zero FDA OAI inspections 2009–2023; mandatory GCP training for all site staff; SMOs shorten time-to-first-patient by 20 days vs. non-SMO sites.
~70% of trial sites use SMO support (unique to Japan); 13 JACIC-affiliated early-phase specialist sites; 403 Phase I trials conducted 2020–2024; Takeda, Astellas, Daiichi Sankyo, Eisai as global pharma anchors; PMDA consultation system reduces downstream risk.
Oncology and rare diseases have driven Japan's shift from primary care to specialist trial activity over the past two decades. Japan's unique cancer burden; gastric cancer, hepatocellular carcinoma, and certain hematologic malignancies show different prevalence or biological characteristics in Japanese patients than in Western populations; makes it irreplaceable for programs seeking globally generalizable data. Cell and gene therapy development is rapidly accelerating, with PMDA having issued conditional approvals for autologous cell therapies and CAR-T products. Japan is also a global leader in regenerative medicine trials under its dedicated Act on the Safety of Regenerative Medicine.
Japan's early-phase activity is concentrated at 13 JACIC-affiliated specialist sites, primarily in Tokyo, Osaka, and Nagoya. For late-phase commercial trials, the major NCI-designated Cancer Centers and university hospital networks anchor enrollment. Tokyo and the Kanto region account for the majority of trial activity, with Osaka-Kyoto and Nagoya as secondary hubs.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | National Cancer Center Hospital | Tokyo | Japan's premier oncology research institution; JACIC member Phase I site; broad Phase I–III portfolio across all major tumor types; East/West campus; ATLAS Asian cancer trial network coordinator; leading gastric, lung, and colorectal cancer research. |
| 02 | The University of Tokyo Medical School Hospital | Tokyo | Japan's oldest and most prestigious university hospital; Phase I–IV across oncology, cardiovascular, neurology, and rare diseases; JACIC Phase I site; strong hematology and rare disease program; Clinical Research Innovation and Education Center (CRIETO). |
| 03 | Keio University Hospital | Tokyo | JACIC Phase I affiliate; oncology, cardiovascular, and regenerative medicine trials; strong industry-sponsored portfolio; Keio Advanced Research Centers partnership; Central Tokyo patient access. |
| 04 | Osaka University Hospital | Osaka | Western Japan's leading academic hospital; JACIC Phase I site; oncology, cardiovascular, and cell therapy trials; Osaka University Immunology Frontier Research Center (IFReC) partnership; access to Kansai region's 20M+ population. |
| 05 | Kindai University Hospital | Osaka | JACIC Phase I affiliate; major hepatocellular carcinoma and GI oncology specialist; liver cancer research is among the world's best; strong Phase I–III HCC and GI program; Osaka regional patient access. |
| 06 | National Cancer Center Hospital East | Kashiwa | NCC East campus; Phase I–III across solid and hematologic malignancies; drug development unit; early-phase specialist; strong in breast, GI, and lung cancer trials; JACIC affiliated. |
| 07 | Nagoya University Hospital | Nagoya | Central Japan anchor site; JACIC Phase I affiliate; oncology, cardiovascular, and rare disease trials; access to Chubu region's 10M+ population; strong Toyota/automotive industry-linked occupational health research. |
| 08 | Kyoto University Hospital | Kyoto | iPS cell research origin institution (Nobel Prize 2012); regenerative medicine and cell therapy trials; oncology, rare disease, and cardiovascular program; Phase I–III; Kyoto University Institute for Advanced Study partnership. |
| 09 | Jichi Medical University Hospital | Shimotsuke, Tochigi | JACIC Phase I specialist site; clinical pharmacology and first-in-human studies; healthy volunteer and early oncology program; strong reputation for PK/PD and thorough QT studies. |
| 10 | Tokyo Women's Medical University Hospital | Tokyo | Women's health, cardiovascular, and organ transplantation specialist; Phase II–III commercial portfolio; access to Tokyo's female patient population; unique women's health research focus. |
| 11 | St. Luke's International Hospital | Tokyo | Japan's leading international-standard private hospital; bilingual English-Japanese research team; oncology and cardiovascular trials; significant international sponsor partnerships; JCI-accredited. |
| 12 | Shizuoka Cancer Center | Shizuoka | Dedicated oncology research hospital; Phase I–III across solid tumors; known for efficient startup and enrollment; strong in thoracic, GI, and breast cancer trials; active Phase I drug development unit. |
| 13 | Tohoku University Hospital | Sendai | Northern Japan anchor; oncology, cardiovascular, and rare disease trials; access to Tohoku region patient population; strong Phase II–III commercial portfolio; Tohoku University Global COE program. |
| 14 | Aichi Cancer Center | Nagoya | Designated NCI-equivalent cancer center; Phase I–III oncology; gastric, colorectal, and hematologic malignancy specialist; strong investigator-initiated and industry-sponsored trial portfolio for Central Japan. |
| 15 | Hokkaido University Hospital | Sapporo | Northern Japan's leading academic hospital; oncology, cardiovascular, and autoimmune disease trials; unique patient population access in Japan's northernmost major city; strong Phase II–III commercial portfolio. |
Japan's premier oncology research institution; JACIC member Phase I site; broad Phase I–III portfolio across all major tumor types; East/West campus; ATLAS Asian cancer trial network coordinator; leading gastric, lung, and colorectal cancer research.
Japan's oldest and most prestigious university hospital; Phase I–IV across oncology, cardiovascular, neurology, and rare diseases; JACIC Phase I site; strong hematology and rare disease program; Clinical Research Innovation and Education Center (CRIETO).
JACIC Phase I affiliate; oncology, cardiovascular, and regenerative medicine trials; strong industry-sponsored portfolio; Keio Advanced Research Centers partnership; Central Tokyo patient access.
Western Japan's leading academic hospital; JACIC Phase I site; oncology, cardiovascular, and cell therapy trials; Osaka University Immunology Frontier Research Center (IFReC) partnership; access to Kansai region's 20M+ population.
JACIC Phase I affiliate; major hepatocellular carcinoma and GI oncology specialist; liver cancer research is among the world's best; strong Phase I–III HCC and GI program; Osaka regional patient access.
NCC East campus; Phase I–III across solid and hematologic malignancies; drug development unit; early-phase specialist; strong in breast, GI, and lung cancer trials; JACIC affiliated.
Central Japan anchor site; JACIC Phase I affiliate; oncology, cardiovascular, and rare disease trials; access to Chubu region's 10M+ population; strong Toyota/automotive industry-linked occupational health research.
iPS cell research origin institution (Nobel Prize 2012); regenerative medicine and cell therapy trials; oncology, rare disease, and cardiovascular program; Phase I–III; Kyoto University Institute for Advanced Study partnership.
JACIC Phase I specialist site; clinical pharmacology and first-in-human studies; healthy volunteer and early oncology program; strong reputation for PK/PD and thorough QT studies.
Women's health, cardiovascular, and organ transplantation specialist; Phase II–III commercial portfolio; access to Tokyo's female patient population; unique women's health research focus.
Japan's leading international-standard private hospital; bilingual English-Japanese research team; oncology and cardiovascular trials; significant international sponsor partnerships; JCI-accredited.
Dedicated oncology research hospital; Phase I–III across solid tumors; known for efficient startup and enrollment; strong in thoracic, GI, and breast cancer trials; active Phase I drug development unit.
Northern Japan anchor; oncology, cardiovascular, and rare disease trials; access to Tohoku region patient population; strong Phase II–III commercial portfolio; Tohoku University Global COE program.
Designated NCI-equivalent cancer center; Phase I–III oncology; gastric, colorectal, and hematologic malignancy specialist; strong investigator-initiated and industry-sponsored trial portfolio for Central Japan.
Northern Japan's leading academic hospital; oncology, cardiovascular, and autoimmune disease trials; unique patient population access in Japan's northernmost major city; strong Phase II–III commercial portfolio.
These are the primary regulatory, academic, and industry bodies shaping Japan's clinical research ecosystem.
National trial and drug regulator; 30-day CTN review; 332-day median MAA approval (2023); ICH member; Project Orbis concurrent oncology review (with FDA, EMA, TGA, Health Canada, MHRA, ANVISA); overseas offices in Bangkok and Washington D.C. (2024).
Policy oversight and drug approval authority; parallel pricing and reimbursement review; NHI listing within 60–90 days of approval; Regenerative Medicine Act administration; drives anti-drug-lag initiatives.
Government R&D funder for clinical research; supports investigator-initiated trials; ARISE and ATLAS multinational clinical trial networks; bridges academia and industry in clinical development.
Premier oncology research institution; East and West campuses; ATLAS Asian cancer trial network; coordinator of multi-regional cancer trials across Asia-Pacific; JACIC Phase I specialist.
Industry body for Japanese pharma companies; clinical trial statistics; SMO usage analysis; anti-drug-lag advocacy; international regulatory harmonization initiatives.
Network of 13 specialist early-phase clinical trial sites; 403 Phase I trials conducted 2020–2024; first-in-human and first-in-Japan study specialist; quality standards for early-phase research in Japan.
Largest CRO operations in Japan; Phase I–IV management; PMDA regulatory expertise; national site network; data analytics; leading international sponsor gateway for Japanese trials.
Japan's largest domestic SMO and CRO group; dispatches clinical research coordinators to ~70% of Japanese trial sites; 110-day time-to-first-patient vs. 130 days without SMO support.
Global CRO with major Japan operations through CMIC partnership; regulatory submissions to PMDA; oncology and rare disease specialty; bridging Japanese and global trial data.
Japan combines high quality clinical infrastructure, PMDA regulatory significance, experienced investigators, and strategic value for Asia Pacific development programs. Its concentrated research networks, aging population, oncology and rare disease capabilities, and established SMO model make the country particularly relevant for sponsors planning globally integrated clinical trials. For teams evaluating clinical trials in Japan, success depends on early regulatory planning, experienced local execution, and careful site selection.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.